Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK Study of Idazoxan Extended-Release Formulations in Healthy Participants
NCT05727189Phase 1Active, not recruiting
- Sponsor
- Terran Biosciences
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of idazoxan (4 arms), sponsored by Terran Biosciences. Primary endpoints: Number of participants with treatment-related adverse events at 25 days, Area under the plasma concentration-time curve at 120 hours and 6 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
idazoxan
Beyond the preview
Go deeper on NCT05727189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727189.